Alder Biopharmaceuticals: eptinezumab met primary endpoint in PROMISE 2 trial
Alder BioPharmaceuticals announced that eptinezumab, its lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide,or CGRP, met the primary endpoint in its pivotal Phase 3 PROMISE 2 clinical trial with very high statistical significance vs. placebo for both dose levels tested in the trial following a single quarterly infusion. In addition, eptinezumab met all key secondary endpoints with very high statistical significance vs. placebo including prevention beginning Day One and 50% and 75 % responder rates month one through month three. Furthermore, 15% of eptinezumab patients had no migraine for a full three months. Safety and tolerability were similar to previously reported eptinezumab studies.